Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer

被引:49
作者
Brockbank, EC
Ind, TEJ
Barton, DPJ
Shepherd, JH
Gore, ME
A'Hern, R
Bridges, JE
机构
[1] Royal Marsden Hosp, Dept Gynaecol Oncol, London SW3 6JJ, England
[2] St Bartholomews Hosp, Gynaecol Canc Ctr, London, England
关键词
CA-125; cytoreduction; ovarian cancer;
D O I
10.1111/j.1048-891x.2004.14065.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Women with epithelial ovarian cancer (EOC) are conventionally treated with primary cytoreductive surgery. For those with a low probability of optimal primary surgical debulking, an alternative management option is primary chemotherapy with delayed primary surgery. Selection criteria are required to identify women who may benefit from this approach. Patients and methods: Patient age, presence of ascites, preoperative serum CA-125 level, surgical procedures performed, postoperative residual disease, FIGO stage, and histology data were collected on 97 women with preoperative clinical evidence of advanced EOC. Univariate and multivariate analysis was performed to identify which preoperative factors predict disease that will be suboptimally debulked. Receiver-operator curves were constructed for CA-125 level as a predictor for residual disease. Results: The best predictor of disease suboptimally cytoreduced was serum CA-125 level (OR = 22.76, 95% CI = 7.13-72.69). Other predictive factors included age over 60 years (OR = 3.16, 95% CI = 1.04-9.56) and clinical evidence of ascites (OR = 3.30, 95% CI = 1.03-10.62). The optimal cut-off for serum CA-125 as a predictor of suboptimal debulking was 586 IU (sensitivity 80.0%, specificity 88.5%, PPV 85.7%). Conclusion: Serum CA-125 level is a reliable component of the preoperative assessment of women with EOC.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 41 条
[1]   Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study [J].
Akahira, JI ;
Yoshikawa, H ;
Shimizu, Y ;
Tsunematsu, R ;
Hirakawa, T ;
Kuramoto, H ;
Shiromizu, K ;
Kuzuya, K ;
Kamura, T ;
Kikuchi, Y ;
Kodama, S ;
Yamamoto, K ;
Sato, S .
GYNECOLOGIC ONCOLOGY, 2001, 81 (03) :398-403
[2]  
Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO
[3]  
2-A
[4]  
CHAMBERS SK, 1988, OBSTET GYNECOL, V72, P404
[5]   ASSESSMENT OF MORBIDITY AND MORTALITY IN PRIMARY CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CARCINOMA [J].
CHEN, SS ;
BOCHNER, R .
GYNECOLOGIC ONCOLOGY, 1985, 20 (02) :190-195
[6]   The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma [J].
Chi, DS ;
Venkatraman, ES ;
Masson, V ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :227-231
[7]   LONG-TERM SURVIVAL IN ADVANCED OVARIAN-CANCER AFTER CYTOREDUCTION AND CHEMOTHERAPY TREATMENT [J].
DELCAMPO, JM ;
FELIP, E ;
RUBIO, D ;
VIDAL, R ;
BERMEJO, B ;
COLOMER, R ;
ZANON, V .
GYNECOLOGIC ONCOLOGY, 1994, 53 (01) :27-32
[8]   PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN CANCER OF THE OVARY [J].
DIRE, F ;
FONTANELLI, R ;
RASPAGLIESI, F ;
DIRE, E .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1989, 3 (01) :131-142
[9]   Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study [J].
Eisenkop, SM ;
Friedman, RL ;
Wang, HJ .
GYNECOLOGIC ONCOLOGY, 1998, 69 (02) :103-108
[10]   Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer [J].
Gemer, O ;
Segal, S ;
Kopmar, A .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (06) :583-585